Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05691504 · ClinicalTrials.gov registry record · Phase 1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
A Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT05691504 is a Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants, below the 228-participant average among 35 other Recurrent Fallopian Tube Carcinoma trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05691504, a Phase 1 study of Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving APG-1252 in combination with cobimetinib may shrink or stabilize tumor in patients with recurrent ovarian and endometrial cancers.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- PROCEDURE Echocardiography Test
- DRUG Cobimetinib
Study Locations (6)
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
- National Cancer Institute Developmental Therapeutics Clinic - Bethesda
- National Institutes of Health Clinical Center - Bethesda
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05691504
The ClinicalTrials.gov registry entry for NCT05691504 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 35 other Recurrent Fallopian Tube Carcinoma trials with a reported enrollment target (82% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Fallopian Tube Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05691504 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05691504 about?
NCT05691504 is a clinical study titled "Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers". This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of pr...
What is the current status of trial NCT05691504?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-09-14. Estimated completion is 2027-02-01.
What conditions does trial NCT05691504 study?
This clinical trial studies the following conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Advanced Endometrial Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma.
What interventions are being tested in trial NCT05691504?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Echocardiography Test (PROCEDURE), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT05691504?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05691504 being conducted?
This trial has 6 study locations across Georgia, Maryland, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Fallopian Tube Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RECRUITING · Phase 1
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Fallopian Tube Carcinoma
All registered trials for this condition
Recurrent Primary Peritoneal Carcinoma
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.